Skip to content
DataLookout
Menu

NCT06016517

Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 5 more changesShow less
    • Start date: Sep 1, 2026 to Dec 1, 2026
    • Eligibility criteria expanded, about 35 words
    • Primary completion pushed from Sep 1, 2028 to Dec 1, 2028
    • Study description expanded, about 7 words
    • Site details revised
  2. Notable Primary completion pushed from Dec 15, 2027 to Sep 1, 2028
    • Start date: May 1, 2026 to Sep 1, 2026
    • Study completion date: Dec 1, 2028 to Dec 15, 2028
    v12
  3. Notable Start date: Mar 15, 2026 to May 1, 2026
    • Primary completion pushed from Aug 15, 2027 to Dec 15, 2027
    v11
  4. Notable Start date: Nov 15, 2025 to Mar 15, 2026v10
  5. Notable Start date: Aug 15, 2025 to Nov 15, 2025v9
Show 7 earlier versionsHide 7 earlier versions
  1. Notable Eligibility criteria expanded, about 121 words
    • Secondary endpoints: 7 to 6
    • Study description expanded, about 57 words
    • Study title expanded, about 7 words
    v8
  2. Notable Primary completion date: May 15, 2026 to Aug 15, 2027
    • Start date: May 15, 2025 to Aug 15, 2025
    • Study completion date: Dec 1, 2026 to Dec 1, 2028
    v7
  3. Notable Primary completion date: Jul 1, 2025 to May 15, 2026
    • Start date: Oct 1, 2024 to May 15, 2025
    • Study completion date: Oct 1, 2025 to Dec 1, 2026
    v6
  4. Notable Start date: Jul 1, 2024 to Oct 1, 2024v5 Show 5 more changesShow less
    • Eligibility criteria expanded, about 21 words
    • Study completion date: Jul 1, 2025 to Oct 1, 2025
    • Interventions: Adalimumab (Drug), Sarilumab (Drug), Upadacitinib (Drug) to Adalimumab (Drug), Etanercept (Drug), Tocilizumab (Drug), Upadacitinib (Drug)
    • Secondary endpoints: details revised at 1 of 7 entries
    • Study description shortened, about 2 words
  5. Notable Start date: May 15, 2024 to Jul 1, 2024
    • Primary and study completion dates: May 15, 2025 to Jul 1, 2025
    v4
  6. Notable Start date: Jan 1, 2024 to May 15, 2024
    • Primary and study completion dates: Jan 1, 2025 to May 15, 2025
    v3
  7. Notable Start date: Oct 1, 2023 to Jan 1, 2024
    • Primary completion date: Oct 1, 2024 to Jan 1, 2025
    • Study completion date: Oct 1, 2025 to Jan 1, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in Disease Activity Score (DAS) 28
Timeframe: Baseline and week 12 of each treatment period

Secondary (6)

Change in The Routine Assessment of Patient Index Data 3 (RAPID3)
Change in American College of Rheumatology 20 (ACR20)
Change in American College of Rheumatology 50 (ACR50)
Change in American College of Rheumatology 70 (ACR70)
The Medical Outcome Study Short-Form 12- item Health Survey (SF-12)
Show 1 moreShow less
Treatment Burden Questionnaire (TBQ)

Arms and interventions

Drugs: Etanercept, Adalimumab, Upadacitinib, Tocilizumab

Sites

1 site in 1 country

  • Tufts Medical CenterBoston, Massachusetts, United States